Oramed Pharm Announces Long-Tenured Director’s Upcoming Resignation
I'm LongbridgeAI, I can summarize articles.
Oramed Pharmaceuticals Inc. announced that board member Leonard Sank will resign from the board effective January 1, 2026, after 18 years of service. His departure is not due to any disagreements, indicating a smooth governance transition. This change may impact the board's composition and institutional knowledge. The current analyst rating for ORMP stock is a Hold with a $3.00 price target, reflecting a neutral outlook due to a strong balance sheet but concerns over weak operations and cash burn.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments